Global Telmisartan Market to Reach USD 4.82 Billion by 2033, Propelled by the Significant Growth in the Pharmaceutical Industry

January 16, 2025 | Healthcare

The latest report by IMARC, titled “Telmisartan Market Report by Indication (Hypertension, Cardiovascular Risk Reduction), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2025-2033”, finds that the global telmisartan market size reached USD 3.83 Billion in 2024. Telmisartan refers to an angiotensin receptor blocker (ARB) that works by blocking a chemical in the human body that tightens blood vessels. It is also primarily used for the treatment of hypertension and cardiovascular risk reduction. It is used alone as well as in combination with several other agents, including amlodipine and hydrochlorothiazide. Nowadays, it is generally available in the form of tablets and oral oil suspension variants and is dispensed with other medications to improve its efficacy. It also helps in relaxing the blood vessels and promoting kidney function. In recent years, telmisartan has gained traction with the rising number of individuals diagnosed with various chronic illnesses.


Global Telmisartan Market Trends:

One of the primary factors driving the market is the significant growth in the pharmaceutical industry. Additionally, the increasing incidences of diabetes, high blood pressure, and numerous kidney-related disorders are creating a positive market outlook. Other than this, telmisartan assists in modifying genes for insulin sensitization, regulating glucose and lipid metabolism, and managing chronic diabetic kidney disease and other disorders. This, coupled with the increasing marketing approvals for generic versions of telmisartan, is propelling the market growth. Besides this, the rising research on telmisartan drugs in emerging nations is escalating the product demand. Furthermore, extensive investment in research and development (R&D) activities by key players to advance telmisartan medications for the treatment of diabetic nephropathy is creating for a favorable market outlook. Other growth-inducing factors include improvements in healthcare infrastructure, rising geriatric population, and increasing number of individuals leading sedentary lifestyles. Looking forward, IMARC Group expects the market value to reach USD 4.82 Billion by 2033, expanding at a CAGR of 2.59% during the forecast period (2025-2033).


Market Summary:

  • Based on the indication, the market has been bifurcated into hypertension and cardiovascular risk reduction.
  • On the basis of the distribution channel, the market has been divided into hospital pharmacies, drug stores and retail pharmacies, and online stores.
  • Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has also been analyzed, with some of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals pls, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.), and Torrent Pharmaceuticals Ltd.

Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Indication, Distribution Channel, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH , Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group

USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Telmisartan Market to Reach USD 4.82 Billion by 2033, Propelled by the Significant Growth in the Pharmaceutical Industry
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials